National Institute of Allergy and Infectious Diseases
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

Radiation Countermeasures
 Program
 Research Areas
 Resources
 Funding
 Summaries and Publications
 Congressional Testimonies


Medical Countermeasures Against Radiological and Nuclear Threats

Centers for Medical Countermeasures Against Radiation (CMCR) Awardees

Columbia University Medical Center, New York, NY
PI: David Brenner
Center for High Throughput, Minimally Invasive, Radiation Biodosimetry  

Dana-Farber Cancer Institute, Boston, MA
PI: Alan D’Andrea
Dana-Farber/Harvard Center for Medical Countermeasures Against Radiation

Duke University Medical Center, Durham, NC
PI: Nelson Chao
Radiation Countermeasures Centers of Research Excellence (RadCCORE)

Fred Hutchinson Cancer Research Center, Seattle, WA
PI: George Georges
Radiation Dose-Dependent Interventions

Medical College of Wisconsin, Milwaukee, WI
PI: John Moulder
Post-Irradiation Intervention to Mitigate and Treat Non-Hematological Injuries

University of California David Geffen School of Medicine, Los Angeles, CA
PI: William McBride
UCLA Center for Biological Radioprotectors

University of Pittsburgh, Pittsburgh, PA
PI: Joel Greenberger
Mitochondrial Targeting Against Radiation Damage

University of Rochester Medical Center, Rochester, NY
PI: Paul Okunieff
Center for Biophysical Assessment and Risk Management Following Irradiation  

CMCR Individual Project Descriptions (PDF)

 

 

 

back to top

Highlights

RFA-09-036: Centers for Medical Countermeasures Against Radiation (U19)

RFP-NIAID-DAIT-NIHAI2009079: Radiation/Nuclear Medical Countermeasure Product Development Support Services

BAA-NIAID-DAIT-NIHAI2009051: Development of Oral Radionuclide Decorporation Agents for Use in Radionuclide Decorporation in Radiological Emergencies

BAA-NIAID-DAIT-NIHAI2009060: Development of Oral Form of Diethylenetriaminepentaacetate (DTPA) for Use in Radionuclide Decorporation – Radiological Emergency 

PA-09-093: Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44]).  Standard SBIR receipt dates.

Solicitation: BAA-BARDA-09-34: BARDA Broad Agency Announcement for the Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures

See Also

  • Radiological and Nuclear Threats News Releases
  • Division of Allergy, Immunology, and Transplantation (DAIT)
  • Biodefense—The NIAID Biodefense Web site includes biodefense-related information for biomedical researchers, the public, and the media.

  • Highlights

    RFA-09-036: Centers for Medical Countermeasures Against Radiation (U19)

    RFP-NIAID-DAIT-NIHAI2009079: Radiation/Nuclear Medical Countermeasure Product Development Support Services

    BAA-NIAID-DAIT-NIHAI2009051: Development of Oral Radionuclide Decorporation Agents for Use in Radionuclide Decorporation in Radiological Emergencies

    BAA-NIAID-DAIT-NIHAI2009060: Development of Oral Form of Diethylenetriaminepentaacetate (DTPA) for Use in Radionuclide Decorporation – Radiological Emergency 

    PA-09-093: Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44]).  Standard SBIR receipt dates.

    Solicitation: BAA-BARDA-09-34: BARDA Broad Agency Announcement for the Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures

    See Also

  • Radiological and Nuclear Threats News Releases
  • Division of Allergy, Immunology, and Transplantation (DAIT)
  • Biodefense—The NIAID Biodefense Web site includes biodefense-related information for biomedical researchers, the public, and the media.